Lamivudine treatment in patients with severely decompensated cirrhosis due to replicating hepatitis b infection

Journal of Hepatology

Volumn 33, Issue 2, 2000, Pages 301-307

  Yao, Francis Y ^a,c   Bass, Nathan M ^b  

^a CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Child's Pugh Turcotte score; Chronic hepatitis B; Decompensated cirrhosis; Lamivudine; Liver transplantation

Indexed keywords

HEPATITIS B ANTIGEN; LAMIVUDINE;

ADULT; AGED; ARTICLE; CHRONIC HEPATITIS; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEPATITIS B; HUMAN; LIVER CIRRHOSIS; LIVER FUNCTION; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME; VIRUS INHIBITION; VIRUS REPLICATION;

EID: 0033929544     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(00)80371-2     Document Type: Article

References (39)

1. Alter MJ, Mast EE. The epidemiology of viral hepatitis in the United States. Gastroenterol Clin North Am. 23:1994;437-455.
2. Maynard JE. Hepatitis B: global importance and need for control. Vaccine. 8:(suppl):1990;518-520.
3. Lee WM. Hepatitis B virus infection. N Engl J Med. 337:1997;1733-1745.
4. Beasley RP, Hwang LY, Lin CC, Chien CS. Hepatocellular carcinoma and hepatitis B virus: a prospective study of 22707 men in Taiwan. Lancet. 2:1981;1129-1133.
5. Liaw YF, Tai DI, Chu CM, Chen TJ. The development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Hepatology. 8:1988;493-496.
6. Fattovich G, Brollo L, Giustina G, Noventa F, Pontisso P, Alberti A, et al. Natural history and prognostic factors for chronic hepatitis type B. Gut. 32:1991;294-298.
7. Perrillo RP. Interferon in the management of chronic hepatitis B. Dig Dis Sci. 38:1993;577-593.
8. Samuel D, Muller R, Alexander G, Fassati L, Ducot B, Benhamou JP, et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med. 329:1993;1842-1847.
9. Pierce GA, Grahm WK, Kaufman HM Jr, Wolf JS. The United Network for Organ Sharing: 1984 to 1994. Transplant Proc. 28:1996;12-15.
10. Keeffe EB. Summary of guidelines on organ allocation and patient listing for liver transplantation. Liver Transplant Surg. 4:(suppl 1):1998;S108-S114.
11. Lai CL, Chien RN, Leung NWY, Chang TT, Guan R, Tai DI, et al. Lamivudine therapy for chronic hepatitis B: a 12 month double-blind, placebo-controlled multicenter study. N Engl J Med. 339:1998;61-68.
12. Dienstag J, Schiff E, Wright T, Perrillo R, Hann HW, Crowther L, et al. Lamivudine treatment for one year in previously untreated U.S. hepatitis B patients: histologic improvement and hepatitis B e-antigen (HBeAg) seroconversion. [abstract] Gastroenterology. 114:1998;1235.
13. Heathcote J, Schalm SW, Cianciara J, Farrell G, Feinmann V, Shermann M, et al. Lamivudine and intron A combination treatment in patients with chronic hepatitis B infection. [Abstract] J Hepatol. 28:(1 suppl):1998;43.
14. Pugh RNH, Murray-Lyon IM, Dawson JL, Pietroni MC, William R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 60:1973;646-649.
15. Selzer ML. The Michigan alcoholism screening test: the quest for a new diagnostic instrument. Am J Psychiatr. 127:1971;1653-1658.
16. Yao F, Osorio R, Roberts J, Poordad F, Steady S, Gish R. Intramuscular hepatitis B immune globulin combined with oral lamivudine for prophylaxis against hepatitis B recurrence after liver transplantation. [abstract] Hepatology. 28:1998;261A.
17. Johnson MA, Horak J, Breuel P. Pharmacokinetics of lamivudine in patients with impaired hepatic function. Eur J Clin Pharm. 54:1998;363-366.
18. Perrillo R, Rakela J, Martin P, Wright T, Levy G, Schiff E, et al. Lamivudine for suppression and/or prevention of hepatitis B when given pre/post liver transplantation. [abstract] Hepatology. 26:1997;260A.
19. Van Thiel DH, Friedlander L, Kania RJ, Molloy PJ, Hassanein T, Wahlstrom E, et al. Lamivudine treatment of advanced and decompensated liver disease due to hepatitis B. Hepatogastroenterology. 44:1997;808-812.
20. Bain VG, Kneteman NM, Ma MM, Gutfreund K, Shapiro JA, Fischer K, et al. Efficacy of lamivudine in chronic hepatitis B patients with active viral replication and decompensated cirrhosis undergoing liver transplantation. Transplantation. 62:1996;1456-1462.
21. Christensen E, Schlichting P, Fauerholdt L, Juhl E, Poulsen H, Tygstrup N. Prognostic value of Child-Turcotte criteria in medically treated cirrhosis. Hepatology. 4:1984;430-435.
22. De Jongh FE, Janssen HLA, De Man RA, Hop WCJ, Schalm SW, Van Blankenstein M. Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver. Gastroenterology. 103:1992;1630-1635.
23. Fattovich G, Giustina G, Schalm SW, Hadziyannis S, Sanchez-Topias J, Almasio P, et al. Occurrence of hepatocellular carcinoma and decompensation in western European patients with cirrhosis type B. Hepatology. 21:1995;77-82.
24. Liaw YF, Lin DY, Chen TJ, Chu CM. Natural course after the development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Liver. 9:1989;235-241.
25. Marcellin P, Colin JF, Boyer N, Bernuau J, Degott C, Hirschauer C, et al. Fatal exacerbation of chronic hepatitis B induced by recombinant alpha-interferon. Lancet. 338:1991;828.
26. Durand JM, Kaplanski G, Portal I, Scheiner C, Berland Y, Soubeyrand J. Liver failure due to recombinant alpha interferon. Lancet. 338:1991;1268-1269.
27. Janssen HL, Brouwer JT, Nevens F, Sanchez-Tapias JM, Craxi A, Hadziyannis S. Fatal hepatic decompensation associated with interferon alfa. BMJ. 306:1993;107-108.
28. Fattovich G, Giustina G, Favorato S, Ruol A. A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon. J Hepatol. 24:1996;38-49.
29. Fattovich G, Giustina G, Realdi G, Corrocher R, Schalm SW. Long-term outcome of hepatitis B e antigen-positive patients with compensated cirrhosis treated with interferon alfa. European Concerted Action on Viral Hepatitis (EUROHEP). Hepatology. 26:1997;1338-1342.
30. Allen M, Deslauriers M, Andrews W, Tipples GA, Walters KA, Tyrrell DLY, et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Hepatology. 27:1998;1670-1677.
31. Tassopoulos NC, Volpes R, Pastore G, Heathcote J, Buti M, Goldin RD, et al. Efficacy of lamivudine in patients with hepatitis B e antigennegative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Hepatology. 29:1999;889-896.
32. Bonino F, Rosina F, Rizzetto M, Rizzi R, Chiaberge E, Tardanico R, et al. Chronic hepatitis in HBsAg carriers with serum HBV-DNA and anti-HBe. Gastroenterology. 90:1986;1268-1273.
33. Carman WF, Jacyna MR, Hadziyannis S, Karayiannis P, McGarvey MJ, Makris A, et al. Mutation preventing formation of e antigen in patients with chronic HBV infection. Lancet. 2:1989;588-591.
34. Brunetto MR, Oliveri F, Rocca G, Criscuolo D, Chiaberge E, Capalbo M, et al. Natural course and response to interferon of chronic hepatitis B accompanied by antibody to hepatitis B e antigen. Hepatology. 10:1989;198-202.
35. Di Bisceglie AM, Hoofnagle JH. Chronic viral hepatitis. Zakim D, Boyer TD. Hepatology: a textbook of liver disease, volume II. 3rd ed. 1996;1299-1329 Saunders, Philadelphia.
36. Dodson SF, Bonham CA, Geller D, Fontes P, Balan V, Vargas H, et al. The role of pre-transplant treatment with lamivudine in hepatitis B surface antigen positive patients undergoing liver transplantation. [Abstract] Liver Transplant Surg. 5:1999;C6.
37. Heathcote EJ, Jeffers L, Wright T, Sherman M, Perrillo R, Sacks S, et al. Loss of serum HBV DNA and HBeAg and seroconversion following short-term (12 weeks) adefovir dipivoxil therapy in chronic hepatitis B: two placebo-controlled phase II studies. [Abstract] Hepatology. 28:1998;317A.
38. Fontana R, Lok ASF. Combination therapy for chronic hepatitis B. Hepatology. 26:1997;234-237.
39. Yao F, Gish RG. Treatment of chronic hepatitis B: new antiviral therapies. Current Gastroenterology Reports. 1:1999;20-26.